We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+6.49%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$541M
Cap. Flow
+$153M
Cap. Flow %
28.31%
Top 10 Hldgs %
65.43%
Holding
52
New
9
Increased
5
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
TIL icon
Instil Bio
TIL
+$39.9M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$24M
3
DBTX
Decibel Therapeutics, Inc. Common Stock
DBTX
+$13M
4
TERN
Terns Pharmaceuticals
TERN
+$10.9M
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$8.66M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$7.26M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$6.65M
3
EQ icon
Equillium
EQ
+$2.22M
4
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$2.17M
5
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$1.27M

Sector Composition

Rank Sector Weight
1 Healthcare 89.56%
2 Financials 1.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDMN
51
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-165,000
Closed -$685
PANA.U
52
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
– –
-400,000
Closed -$5.1K
1 2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q1 2021 Portfolio in Review

As of Q1 2021, Samsara BioCapital held 52 positions worth $542M, up 54,424% from $994K the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Samsara BioCapital deployed $153M of net new capital in Q1 2021, opening 9 new positions and adding to 5 existing holdings. Its largest new stake was Instil Bio: 77,701 shares worth $39M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 48% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $7.26M trimmed.

  • Samsara BioCapital's largest Q1 2021 buy was Instil Bio: 77,701 shares worth $39M.
  • Samsara BioCapital added most to Intercept Pharmaceuticals, Inc. in Q1 2021, an estimated $6.61M increase.
  • Samsara BioCapital's biggest Q1 2021 reduction was SpringWorks Therapeutics, cutting an estimated $7.26M.
  • Samsara BioCapital fully exited Cogent Biosciences in Q1 2021, selling an estimated $6.61K.
  • Samsara BioCapital's ten largest holdings make up 65% of its $542M portfolio in Q1 2021.
  • Samsara BioCapital opened 9 new positions and closed 8 in Q1 2021.
  • Samsara BioCapital's portfolio value rose 54,424% quarter-over-quarter to $542M.

Based on Samsara BioCapital's 13F filing for Q1 2021, filed 18 May 2021.